| Size | Price | Stock | Qty |
|---|---|---|---|
| 50g |
|
||
| 100g |
|
||
| Other Sizes |
Purity: ≥98%
| Targets |
DM-β-CD does not have a defined pharmacological target. It is a pharmaceutical excipient used to improve the solubility and bioavailability of poorly soluble drugs. Its mechanism of action involves the formation of inclusion complexes: its hydrophilic exterior allows it to interact with water, while its hydrophobic cavity can encapsulate lipophilic drug molecules. This enhances drug dissolution and absorption.
|
|---|---|
| ln Vitro |
For life science-related study, DM-β-CD is a biochemical reagent that can be utilized as an organic substance or biological material.
In vitro, DM-β-CD is used as a solubilizer and carrier for poorly soluble drugs in pharmaceutical formulations. It enhances the solubility and stability of poorly soluble drugs, making it a valuable excipient in the development of oral and injectable medications. It is used to measure the equilibrium constant of its complexes with various enantiomeric pairs of chiral nitroxides by EPR spectroscopy. |
| ln Vivo |
In vivo, DM-β-CD is used to improve the solubility and bioavailability of poorly soluble drugs. By forming inclusion complexes with drug molecules, it enhances drug dissolution and absorption in the gastrointestinal tract. The compound is used as an excipient in pharmaceutical formulations for oral and injectable medications. It is also used as a stabilizer in pharmaceutical preparations.
|
| Enzyme Assay |
For in vitro complexation studies, DM-β-CD is used to measure the equilibrium constant of its complexes with various guest molecules. Standard protocols involve dissolving the cyclodextrin and guest molecule in appropriate buffer and measuring the binding affinity using techniques such as isothermal titration calorimetry (ITC), NMR spectroscopy, or fluorescence spectroscopy. The compound's ability to form inclusion complexes with aromatic compounds, pesticides, and heavy metals is also studied.
|
| Cell Assay |
For in vitro cell-based experiments, DM-β-CD is not typically used directly in cell culture as a test compound. It is a pharmaceutical excipient used to formulate drug-cyclodextrin complexes that are then tested in cell-based assays. The compound's biocompatibility and lack of cytotoxicity make it suitable for use in drug delivery formulations.
|
| Animal Protocol |
For in vivo animal studies, DM-β-CD is used as an excipient in drug formulations to improve the bioavailability of poorly soluble drugs. Drug-cyclodextrin complexes are administered to rodents via oral gavage or intravenous injection. Pharmacokinetic parameters such as Cmax, AUC, and bioavailability are compared between drug alone and drug-cyclodextrin complex formulations.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of DM-β-CD as a standalone compound are not extensively characterized. The compound is a cyclodextrin derivative with molecular weight of approximately 1331.36 g/mol. As a large, hydrophilic molecule, it is not significantly absorbed from the gastrointestinal tract. The compound is primarily used as an excipient to improve the pharmacokinetics of other drugs.
|
| Toxicity/Toxicokinetics |
DM-β-CD is generally considered to be non-toxic and biocompatible. It is used as a pharmaceutical excipient in oral and injectable formulations. The compound has low oral toxicity and is not significantly absorbed systemically. Standard laboratory safety practices should be followed when handling the compound. Specific LD₅₀ values and toxicity classifications are available from safety data sheets.
|
| Additional Infomation |
Bordetella pertussis stimulant Phase I
DM-β-CD (2,6-Di-O-methyl-β-cyclodextrin, CAS 51166-71-3) is a pharmaceutical excipient, not an FDA-approved drug. Its primary applications are as a solubilizer and carrier for poorly soluble drugs in pharmaceutical formulations. It is also used in analytical chemistry, food science, and environmental remediation. The compound's ability to form inclusion complexes with lipophilic drugs improves their solubility and bioavailability. No clinical trials or approved indications exist for this compound as a drug. |
| Molecular Formula |
C56H98O35
|
|---|---|
| Molecular Weight |
1331.36
|
| Exact Mass |
1330.588
|
| CAS # |
51166-71-3
|
| PubChem CID |
10171019
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
1203.6±65.0 °C at 760 mmHg
|
| Melting Point |
298 - 310ºC
|
| Flash Point |
681.7±34.3 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.553
|
| LogP |
6.96
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
35
|
| Rotatable Bond Count |
21
|
| Heavy Atom Count |
91
|
| Complexity |
1690
|
| Defined Atom Stereocenter Count |
35
|
| SMILES |
O1[C@]2([H])[C@@]([H])([C@]([H])([C@@]([H])([C@@]([H])(C([H])([H])OC([H])([H])[H])O2)O[C@]2([H])[C@@]([H])([C@]([H])([C@@]([H])([C@@]([H])(C([H])([H])OC([H])([H])[H])O2)O[C@]2([H])[C@@]([H])([C@]([H])([C@@]([H])([C@@]([H])(C([H])([H])OC([H])([H])[H])O2)O[C@]2([H])[C@@]([H])([C@]([H])([C@@]([H])([C@@]([H])(C([H])([H])OC([H])([H])[H])O2)O[C@]2([H])[C@@]([H])([C@]([H])([C@@]([H])([C@@]([H])(C([H])([H])OC([H])([H])[H])O2)O[C@]2([H])[C@@]([H])([C@]([H])([C@@]([H])([C@@]([H])(C([H])([H])OC([H])([H])[H])O2)O[C@]2([H])[C@@]([H])([C@]([H])([C@@]1([H])[C@@]([H])(C([H])([H])OC([H])([H])[H])O2)O[H])OC([H])([H])[H])O[H])OC([H])([H])[H])O[H])OC([H])([H])[H])O[H])OC([H])([H])[H])O[H])OC([H])([H])[H])O[H])OC([H])([H])[H])O[H])OC([H])([H])[H]
|
| InChi Key |
QGKBSGBYSPTPKJ-UZMKXNTCSA-N
|
| InChi Code |
InChI=1S/C56H98O35/c1-64-15-22-36-29(57)43(71-8)50(78-22)86-37-23(16-65-2)80-52(45(73-10)30(37)58)88-39-25(18-67-4)82-54(47(75-12)32(39)60)90-41-27(20-69-6)84-56(49(77-14)34(41)62)91-42-28(21-70-7)83-55(48(76-13)35(42)63)89-40-26(19-68-5)81-53(46(74-11)33(40)61)87-38-24(17-66-3)79-51(85-36)44(72-9)31(38)59/h22-63H,15-21H2,1-14H3/t22-,23-,24-,25-,26-,27-,28-,29+,30+,31+,32+,33+,34+,35+,36-,37-,38-,39-,40-,41-,42-,43-,44-,45-,46-,47-,48-,49-,50-,51-,52-,53-,54-,55-,56-/m1/s1
|
| Chemical Name |
(1S,3R,5R,6S,8R,10R,11S,13R,15R,16S,18R,20R,21S,23R,25R,26S,28R,30R,31S,33R,35R,36S,37R,38S,39R,40S,41R,42S,43R,44S,45R,46S,47R,48S,49R)-37,39,41,43,45,47,49-heptamethoxy-5,10,15,20,25,30,35-heptakis(methoxymethyl)-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontane-36,38,40,42,44,46,48-heptol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 500 mg/mL (375.56 mM)
H2O: 125 mg/mL (93.89 mM) |
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.7511 mL | 3.7556 mL | 7.5111 mL | |
| 5 mM | 0.1502 mL | 0.7511 mL | 1.5022 mL | |
| 10 mM | 0.0751 mL | 0.3756 mL | 0.7511 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA